ThromboGenics NV has announced the publication of a paper in the prestigious journal Cell, highlighting the potential of TB-403 to improve the treatment of medulloblastoma, the most common brain tumor in children.
The Cell publication highlights for the first time a new mechanism of action showing that PlGF plays a vital role in the brain and that its expression is required for the growth and spread of medulloblastoma.
The novel positive findings in this paper provide evidence that could warrant further development of TB-403 as one of the first targeted therapies to treat this childhood cancer. TB-403 is a monoclonal antibody against placental growth factor (PlGF).
PIGF is a naturally occurring protein that belongs to the family of vascular endothelial growth factors (VEGF) that promote the formation of blood vessels.
TB-403 was in-licensed by ThromboGenics from the Flanders Institute for Biotechnology (VIB), where the therapeutic potential of anti-PlGF agents to treat cancer was first developed by Prof. Peter Carmeliet at the University of Leuven, Belgium.
This Cell paper is reporting the findings of new pre-clinical research performed at the Massachusetts General Hospital in Harvard (Boston), in collaboration with the team of Prof Peter Carmeliet.
With an emerging ophthalmologic franchise, Thrombogenics is also evaluating the role of TB-403 for ophthalmic indications.